The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs raises methanex price target to sixty six maintains buy rating
UBS has raised its price target for Methanex Corporation to $66 from $53, maintaining a Buy rating, as six analysts have revised earnings estimates upward. Despite expected declines in methanol prices due to increased supply, a market retightening is anticipated later this year, supporting stable pricing. Methanex's recent financial results showed an adjusted EBITDA of $216 million, with analysts from BMO and Piper Sandler also increasing their price targets, reflecting confidence in the company's operational performance and strategic shifts.
ubs downgrades fmc stock to neutral slashes price target to thirty eight dollars
UBS has downgraded FMC Corp. from Buy to Neutral, slashing the price target from $66 to $38 due to concerns over the company's near-term prospects and long-term challenges. The stock has plummeted over 36% recently, trading near its 52-week low, as analysts express worries about competitive pressures and sustainability of dividends. Despite a solid dividend yield and potential volume growth from new products, risks related to sales strategy and pricing pressures have led to a cautious outlook for the company.
ubs downgrades fmc stock to neutral amid declining outlook and challenges
UBS has downgraded FMC Corp. from Buy to Neutral, slashing its price target from $66 to $38 due to concerns over the company's near-term outlook and long-term challenges. The stock has plummeted over 36% recently, trading near its 52-week low, as analysts express worries about competitive pressures and dividend sustainability. Despite a solid dividend yield and recent earnings beat, FMC's revenue fell short of expectations, prompting multiple analysts to downgrade their ratings.
ubs raises linde price target to 485 maintains neutral rating
UBS has upgraded its price target for Linde plc from $465 to $485 while maintaining a 'Neutral' rating. The industrial gases group met expectations in its quarterly performance, although the outlook for 2025 fell slightly short. As of February 6, 2025, Linde shares are trading at €430.8, down 1.28%.
UBS raises Linde PLC price target while maintaining neutral rating
UBS has raised its price target for Linde PLC from $465 to $485, maintaining a "Neutral" rating following the company's quarterly results. Analyst Joshua Spector noted that while the performance was largely in line with expectations, the outlook for 2025 fell slightly short.
ubs lowers cabot corp price target while maintaining neutral rating
UBS has lowered its price target for Cabot Corp to $93 while maintaining a Neutral rating, citing the stock's undervaluation and strong financial performance, including an EPS of $1.76 that exceeded expectations. Despite mixed results in revenue, the company reaffirmed its full-year guidance, supported by solid performance in its Reinforcement Materials and Performance segments. Mizuho Securities also adjusted its price target to $105, highlighting the impact of market developments and contract pricing in the tire manufacturing sector.
ubs raises air products stock target amid board changes and strong earnings
UBS analyst Joshua Spector has raised the price target for Air Products & Chemicals Inc. to $385, maintaining a Buy rating, citing positive catalysts and a conservative earnings outlook. The company, which has a strong history of dividend payments, recently underwent a significant board refresh, with three new directors elected from activist investor Mantle Ridge. Additionally, Air Products reported robust preliminary earnings for Q1 FY2025, exceeding expectations, and announced a CEO succession plan set for early 2025.
ubs upgrades westlake chemical to buy with positive market outlook
UBS analyst Joshua Spector upgraded Westlake Chemical (NYSE: ) from Neutral to Buy, setting a price target of $144, citing a positive outlook on earnings and valuation. He noted that the stock is trading at a low multiple relative to its potential, particularly with anticipated improvements in the housing market and strong performance in the Housing & Infrastructure segment. Despite operational challenges, Westlake reported Q3 net sales of $3.1 billion and a net income of $183 million, while continuing its dividend payments.
Westlake Chemical stock upgraded to buy with positive earnings outlook
UBS analyst Joshua Spector upgraded Westlake Chemical to a Buy rating, setting a price target of $144, citing a positive outlook on earnings and valuation. He noted that the stock is undervalued at approximately 6.5 times estimated 2025 EBITDA, with key products well-positioned for market recovery. The company's Housing & Infrastructure segment is expected to benefit from a potential U.S. housing market recovery, while recent earnings showed resilience despite challenges.
ubs maintains neutral rating for nutrien with target price of 51 dollars
UBS has maintained a "Neutral" rating for Nutrien, setting a target price of 51 US dollars. The fertilizer company's third-quarter results met expectations but fell slightly short of consensus, with a notably weak operating result. Despite this, Nutrien is advancing in cost management and investments.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.